Alacris Theranostics GmbH (www.alacris.de) is a SME focusing on developing new approaches for personalised medicine, including Next Generation Sequencing (NGS) based treatment guidance, clinical trial stratification, biomarker discovery and advanced bioinformatics. Alacris holds an exclusive worldwide commercial license for the systems biology modelling system ModCell^TM, a technology developed with the Max Planck Institute for Molecular Genetics, Berlin. The company is currently involved in a number of major research projects, contributing a range of technologies and expertise, including database creation and management, NGS, and development of the ModCell^TM software for virtual patient modelling.

Current projects include: CanPathPro (H2020), iPC (H2020), 3TR (IMI), Treat20 (BMBF), Tregeneration (H2020), ProSeqo (H2020) and SMARTool (H2020).

Within Cancer-ID, Alacris will participate as WP3 leader. Major tasks include establishment of a data integration platform, which will act as a central repository for the deposition of all primary data and standard operating procedures (SOPs) generated within the project. Alacris will also be involved in establishing SOPs and implementing analysis pipelines for identification of disease biomarkers.